Monthly Archives: May 2024

Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

31/05/2024 – AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

AB Science webcast of May 30, 2024

30/05/2024 – Presentation of the AB Science webcast held on May 30, 2024

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS

Corrective statement on the consolidated accounts as of December 31, 2023

17/05/2024 – AB Science communicates a corrective statement on the consolidated accounts as of December 31, 2023

Annual financial results as of 31 December, 2023

15/05/2024 – AB Science reports its revenues for the year 2023 and provides an update on its activities

AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036

13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib

A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patients

07/05/2024 – AB Science today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine

The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

02/05/2024 – AB Science announced today that the Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science